Use of Articles in the Pachyonychia Congenita Bibliography

The articles in the PC Bibliography may be restricted by copyright laws. These have been made available to you by PC Project for the exclusive use in teaching, scholarship or research regarding Pachyonychia Congenita.

To the best of our understanding, in supplying this material to you we have followed the guidelines of Sec 107 regarding fair use of copyright materials. That section reads as follows:

Sec. 107. - Limitations on exclusive rights: Fair use
Notwithstanding the provisions of sections 106 and 106A, the fair use of a copyrighted work, including such use by reproduction in copies or phonorecords or by any other means specified by that section, for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright. In determining whether the use made of a work in any particular case is a fair use the factors to be considered shall include - (1) the purpose and character of the use, including whether such use is of a commercial nature or is for nonprofit educational purposes; (2) the nature of the copyrighted work; (3) the amount and substantiality of the portion used in relation to the copyrighted work as a whole; and (4) the effect of the use upon the potential market for or value of the copyrighted work. The fact that a work is unpublished shall not itself bar a finding of fair use if such finding is made upon consideration of all the above factors.

We hope that making available the relevant information on Pachyonychia Congenita will be a means of furthering research to find effective therapies and a cure for PC.
Failure of etretinate therapy in pachyonychia congenita

Madam, We describe here the failure of etretinate treatment in a child with pachyonychia congenita. Lesions of pachyonychia usually persist for life and treatment is directed towards relief of the hyperkeratosis by topical keratolytic agents or oral vitamin A or both. Oral retinoids have been reported to be effective not only in the treatment of severe keratinization disorders but also in pachyonychia congenita.

A 10-year-old girl, daughter of unrelated parents, had hyperkeratotic patches with well defined borders on the palms and soles with hyperhidrosis. Her fingernails and toenails were thickened and the undersurface was filled with a yellowish hyperkeratotic material (Fig. 1). Examination was otherwise normal. Laboratory investigations showed normal values for: CBC, ESR, SGOT, SGPT, and serum vitamin A level. Mycological examination of nails and skin scrapings was negative. Skin biopsy showed no abnormality except hyperkeratosis.

The patient was treated orally with etretinate (Tigason) 1 mg/kg/day. After 10 days of therapy excessive skin dryness, erythema, scaling and fissuring of the lips and perioral area, and glossitis with a burning sensation occurred and the dose was decreased to 0.5 mg/kg/day. Since there was no improvement in 5 weeks, the therapy stopped. In contrast to the report by Schönfeld we failed to demonstrate any beneficial effect from 5-week course of etretinate therapy.

Dermatology Department, Erciyes University, Medical Faculty 38039 Kayseri, Turkey.

Ü. Soyuer
M. F. Candan

REFERENCE